1. Red-hot biotechs to take spotlight at ASH virtual meeting — Moderna's 3-month data raise hopes for COVID-19 vaccine durability — BioNTech founder vaults into world's 500 richest — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Alexion beats Q1 earnings and sales estimates; raises guidance

Discussion in 'Alexion' started by anonymous, Apr 26, 2018 at 2:17 PM.

  1. anonymous

    anonymous Guest

    Alexion reported a rise in Q1 2018 earnings and revenue, and lifted the guidance for the year. Along with this, the company also reported a positive top line results for its Phase 3 study.
    The company that specializes in manufacturing drugs for rare disorder reported a 7% increase in its revenue to $930.9 million. Earnings per share rose 48% to $1.11 and excluding items, the company’s earnings per share rose 22% during the quarter.
    Net product sales of the key drug Soliris, which accounts for a bulk of the company’s revenue and is used to treat serious genetic-based blood condition, grew 2% during the quarter to $800.1 million.
    https://news.alphastreet.com/alexion-beats-earnings-and-sales-estimates-raises-guidance/
     

  2. anonymous

    anonymous Guest

    Soliris growth considered an underperform, 2% growth not good. Countries like Brazil will push back on price, Wilson a bad bolt on for the free cash spend. People rejoicing at a $118.17 share, 2.5 years ago stocks was over $200.00. The Headline needs to be the stock and bonus of the executive team, unbelievable.
     
  3. anonymous

    anonymous Guest

    200 / share reflected the Synageva assets and Kanuma and SB103 being viable drugs and contributing significantly to the top line.

    Obviously that was the worse transaction and diligence in the history of acquisitions (not for the Synageva people).

    The entire expect team responsible for that deal has been terminated, and rightfully so.

    Perhaps a large elephant in the room, since the synageva deal didn’t workout as planned, when do they buck up and take the right down for the drug....that will be a 6-7 billion dollar charge.